Zacks Investment Research cut shares of Pfenex (NYSEAMERICAN:PFNX) from a buy rating to a hold rating in a research report released on Friday morning.
According to Zacks, “Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf?nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California. “
Separately, William Blair reaffirmed an outperform rating on shares of Pfenex in a report on Friday, March 16th.
A number of large investors have recently bought and sold shares of the business. Sanders Morris Harris LLC boosted its holdings in Pfenex by 35.6% in the fourth quarter. Sanders Morris Harris LLC now owns 1,353,604 shares of the biotechnology company’s stock valued at $3,600,000 after purchasing an additional 355,453 shares during the last quarter. Millennium Management LLC boosted its holdings in Pfenex by 61.3% in the fourth quarter. Millennium Management LLC now owns 359,288 shares of the biotechnology company’s stock valued at $956,000 after purchasing an additional 136,514 shares during the last quarter. Deutsche Bank AG boosted its holdings in Pfenex by 7.2% in the fourth quarter. Deutsche Bank AG now owns 332,060 shares of the biotechnology company’s stock valued at $883,000 after purchasing an additional 22,392 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Pfenex by 1.1% in the fourth quarter. Franklin Resources Inc. now owns 2,783,060 shares of the biotechnology company’s stock valued at $7,403,000 after purchasing an additional 31,295 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Pfenex by 26.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,010,600 shares of the biotechnology company’s stock valued at $2,688,000 after purchasing an additional 210,600 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Lowers Pfenex (PFNX) to Hold” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3300984/zacks-investment-research-lowers-pfenex-pfnx-to-hold.html.
Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.